Have a feature idea you'd love to see implemented?
Let us know!
HBIO Harvard Bioscience Inc
Price (delayed)
$2.08
Market cap
$90.72M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$130.72M
Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned
Highlights
HBIO's quick ratio is down by 10% YoY but it is up by 4.1% QoQ
The company's net income fell by 33% QoQ
The EPS has contracted by 32% from the previous quarter
Key stats
What are the main financial stats of HBIO
Market
Valuations
Earnings
Shares outstanding
43.62M
Market cap
$90.72M
Enterprise value
$130.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.39
Price to sales (P/S)
0.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.34
Revenue
$97.73M
Gross profit
$57.08M
Net income
-$14.24M
EBIT
-$10.21M
EBITDA
-$3.03M
Free cash flow
-$132,000
Per share
Balance sheet
Liquidity
EPS
-$0.33
EPS diluted
-$0.33
Free cash flow per share
$0
Book value per share
$1.5
Revenue per share
$2.24
TBVPS
$1.41
Total assets
$131.24M
Total liabilities
$65.92M
Debt
$44.56M
Equity
$65.32M
Working capital
$24.04M
Debt to equity
0.68
Current ratio
2.06
Quick ratio
0.76
Net debt/EBITDA
-13.18
Margins
Efficiency
Dividend
EBITDA margin
-3.1%
Gross margin
58.4%
Net margin
-14.6%
Operating margin
-6.1%
Return on assets
-10.7%
Return on equity
-20.8%
Return on invested capital
-13.6%
Return on capital employed
-9.4%
Return on sales
-10.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HBIO stock price
How has the Harvard Bioscience stock price performed over time
Intraday
-0.95%
1 week
-4.15%
1 month
-8.37%
1 year
-61.48%
YTD
-61.12%
QTD
-22.68%
Financial performance
How have Harvard Bioscience's revenue and profit performed over time
Revenue
$97.73M
Gross profit
$57.08M
Operating income
-$5.94M
Net income
-$14.24M
Gross margin
58.4%
Net margin
-14.6%
Harvard Bioscience's net margin has decreased by 38% from the previous quarter
The company's net income fell by 33% QoQ
Harvard Bioscience's operating margin has decreased by 24% from the previous quarter
HBIO's operating income is down by 19% since the previous quarter
Growth
What is Harvard Bioscience's growth rate over time
Valuation
What is Harvard Bioscience stock price valuation
P/E
N/A
P/B
1.39
P/S
0.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.34
The EPS has contracted by 32% from the previous quarter
HBIO's price to book (P/B) is 42% less than its 5-year quarterly average of 2.4 and 42% less than its last 4 quarters average of 2.4
The equity has declined by 12% year-on-year and by 2.9% since the previous quarter
The stock's price to sales (P/S) is 42% less than its 5-year quarterly average of 1.6 and 38% less than its last 4 quarters average of 1.5
Harvard Bioscience's revenue has decreased by 13% YoY and by 3.4% from the previous quarter
Efficiency
How efficient is Harvard Bioscience business performance
The ROS has plunged by 68% from the previous quarter
HBIO's return on invested capital has dropped by 64% since the previous quarter
The return on equity has declined by 38% since the previous quarter
The return on assets has declined by 35% since the previous quarter
Dividends
What is HBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HBIO.
Financial health
How did Harvard Bioscience financials performed over time
The total assets is 99% more than the total liabilities
HBIO's quick ratio is down by 10% YoY but it is up by 4.1% QoQ
Harvard Bioscience's total liabilities has increased by 7% from the previous quarter
Harvard Bioscience's debt is 32% less than its equity
The company's debt to equity rose by 13% QoQ and by 11% YoY
The equity has declined by 12% year-on-year and by 2.9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.